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Heme oxygenase-1 may exert cytoprotective effects. In this
study we examined the sensitivity of heme oxygenase-1
knockout (HO-1/) mice to renal ischemia by assessing
glomerular filtration rate (GFR) and cytokine expression in
the kidney, and inflammatory responses in the systemic
circulation and in vital extrarenal organs. Four hours after
renal ischemia, the GFR of HO-1/ mice was much lower
than that of wild-type mice in the absence of changes in
renal blood flow or cardiac output. Eight hours after renal
ischemia, there was a marked induction of interleukin-6 (IL-6)
mRNA and its downstream signaling effector,
phosphorylated signal transducer and activator of
transcription 3 (pSTAT3), in the kidney, lung, and heart in
HO-1/ mice. Systemic levels of IL-6 were markedly and
uniquely increased in HO-1/ mice after ischemia as
compared to wild-type mice. The administration of an
antibody to IL-6 protected against the renal dysfunction and
mortality observed in HO-1/ mice following ischemia. We
suggest that the exaggerated production of IL-6, occurring
regionally and systemically following localized renal
ischemia, in an HO-1-deficient state may underlie the
heightened sensitivity observed in this setting.
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Ischemic insults, localized to the kidney, elicit responses both
within and beyond the injured organ. Regional responses in
the ischemic kidney may either promote or mitigate renal
injury, and among the maladaptive, injurious responses
considerable attention is directed to processes that come
under the rubric of inflammation.1–6 These processes involve
any one or combination of the following: monocytes/
macrophages, neutrophils, B and T lymphocytes, dendritic
cells, as well as assorted cytokines, chemokines, and adhesion
molecules.1–6 Along with these and other potentially
injurious mechanisms, ischemia also elicits cytoprotective
responses which can lessen the severity of ensuing injury by
suppressing, at least in part, renal inflammation.7,8
Localized renal ischemia, however, may exert effects that
go beyond the confines of the kidney and involve much more
than the predictable complications—fluid accumulation and
alterations in chemical composition of plasma—occasioned
by impaired renal function. Ischemic episodes, restricted to
the kidney, can lead to unrestricted inflammatory processes
which are widely conveyed by the systemic circulation to
organs and tissues far removed from the ischemic kidney.1–12
Localized renal ischemia of sufficient severity, and indepen-
dent of derangements in fluid and electrolytes, may thus be
viewed as an instigator of a systemic inflammatory process
with abnormalities appearing in distant organs.
The present studies explored the role of heme oxygenase-1
(HO-1) in influencing renal and systemic responses that
occur in the early phase after an acute episode of renal
ischemia. HO is the rate-limiting enzyme in the degradation of
heme, and such activity is possessed by two isozymes: HO-1,
the inducible isoform which can exert cytoprotective proper-
ties in injured tissue, and HO-2, the constitutive isoform.13–18
These studies represent the continuation of an investigative
line initiated by the demonstration that induction of HO-1 in
the kidney exposed to heme proteins conferred marked
cytoprotective effects.19 As HO-1 was subsequently shown to
be induced in the kidney subjected to ischemia, the question
inevitably arose whether such induction of HO-1 in the
ischemic kidney was adaptive or maladaptive in nature.
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While studies based on the use of pharmacologic inhibitors
of HO activity to examine this issue yielded conflicting
results,20,21 an approach based on HO-1/ mice demon-
strated that such a genetic deficiency markedly increases the
sensitivity to renal injury, as reflected by increased blood urea
nitrogen (BUN) and serum creatinine measured 24 h after
the ischemic insult, and increased mortality following the
ischemic episode.22
This study was undertaken to further analyze the basis for
such sensitivity, and began with an analysis of the renal
hemodynamic and inflammatory responses in the early phase
after ischemia. As the previously observed mortality in
HO-1/ mice subjected to ischemia–reperfusion injury was
not readily explained by renal dysfunction,22 analyses of
relevant cytokine expression in the systemic circulation and
distant vital organs were also undertaken.
RESULTS
Renal hemodynamic studies at 4 h after ischemia–reperfusion
HO-1/ mice subjected to ischemia–reperfusion exhibited
significant impairment in glomerular filtration rate (GFR) as
compared to similarly treated HO-1þ /þ mice (Figure 1).
These changes were not associated with impairment in renal
blood flow (RBF) or an increase in renal vascular resistance,
but were accompanied by a lower filtration fraction. Mean
arterial pressure (MAP) was comparable in HO-1þ /þ mice
and HO-1/ mice subjected to ischemia–reperfusion (9472
versus 9873 mm Hg, P¼NS). Mean kidney weights were
greater in HO-1/ mice as compared with HO-1þ /þ mice
after ischemia–reperfusion (0.3370.03 versus 0.4470.02 g,
Po0.05), but not after sham ischemia (0.3170.03 versus
0.3470.02 g, P¼NS). GFR factored for kidney weight was
significantly lower in HO-1/ mice as compared with
HO-1þ /þ mice after ischemia (0.6670.04 versus
0.2070.10 ml/min/g, Po0.05). Although less pronounced
than after ischemia, GFR and filtration fraction were
impaired in HO-1/ mice as compared with HO-1þ /þ
mice following sham ischemia (Figure 1). Studies of cardiac
function, undertaken 4 h after ischemia, revealed no
significant differences among all four groups in any of the
assessed indices, in particular cardiac output (Figure 2).
Expression of HO-1 in the kidney 4 h after ischemia–reperfu-
sion
HO-1 mRNA was induced fivefold in the kidney of HO-1þ /þ
mice following ischemia and was accompanied by more
abundant expression of HO-1 protein; HO-1 mRNA and
protein were essentially undetectable in the kidneys of HO-1/
mice subjected to either condition (Figure 3).
Expression of IL-6 and other cytokines in the kidney 8 h after
ischemia–reperfusion
Expression of selected cytokines relevant to renal ischemia
was variably increased in the ischemic kidney in HO-1/
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Figure 1 | Renal hemodynamics in HO-1þ /þ and HO-1/ mice
subjected to ischemia–reperfusion injury (IR) or sham ischemia
(Sham). The data demonstrate the following hemodynamic
parameters: glomerular filtration rate (GFR), renal blood flow (RBF),
renal vascular resistance (RVR), and filtration fraction (FF). n¼ 4 in
each of the HO-1þ /þ and HO-1/ groups subjected to sham
ischemia; n¼ 6 and n¼ 8 (GFR), and n¼ 5 and n¼ 7 (RBF, RVR, and
FF) in HO-1þ /þ and HO-1/ groups subjected to IR respectively.
*Po0.05 versus HO-1þ /þ mice subjected to the same condition.
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Figure 2 | Cardiac function in HO-1þ /þ and HO-1/ mice
subjected to ischemia–reperfusion injury (IR) or sham ischemia
(Sham). The data demonstrate the following: heart rate (beats per
minute), circumferential shortening velocity (circumferences/s),
fractional shortening (%), and cardiac output (ml/min/30 g). n¼ 5
in each of the HO-1þ /þ Sham and HO-1þ /þ IR groups, and n¼ 6 in
each of HO-1/ Sham and HO-1/ IR groups.
1074 Kidney International (2007) 72, 1073–1080
o r i g i n a l a r t i c l e MJ Tracz et al.: Deficiency of HO-1 worsens renal ischemia
mice as compared with HO-1þ /þ mice (Table 1). Inter-
leukin-6 (IL-6) was dramatically induced in the kidney
following ischemia in HO-1/ mice as compared with
HO-1þ /þ mice (Figure 4).
Expression of IL-6-dependent signaling in the kidney 8 h after
ischemia–reperfusion
As IL-6 activates the Janus kinase/signal transducer and
activator of transcription (JAK/STAT) pathway, in particular,
signal transducer and activator of transcription 3 (STAT3),23
the latter was assessed after ischemia. Phosphorylated signal
transducer and activator of transcription 3 (pSTAT3), the
activated form of STAT3, but not STAT3 itself, was markedly
induced in HO-1/ mice after ischemia, whereas all other
groups failed to evince such changes (Figure 5).
Concentration of serum cytokines at 8 h after renal ische-
mia–reperfusion
Of these measured cytokines (Table 2 and Figures 6, 7 and 8),
the striking finding was that only IL-6 showed the profile
depicted in Figure 6, namely, a markedly increased serum
level in HO-1/ mice after ischemia as compared to the
other three groups, with comparable IL-6 levels in HO-1/
and HO-1þ /þ mice subjected to sham ischemia (Figure 6).
The only other cytokine that was elevated in HO-1/ mice
at this time point after ischemia–reperfusion was IL-12 (p40);
however, a similar elevation in IL-12 (p40) in HO-1/ mice
was also observed after sham ischemia (Figure 7). IL-5 and
macrophage inflammatory protein-1a decreased in HO-1/
mice following ischemia–reperfusion (Figure 8). All other
cytokines were unchanged (Table 2).
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Figure 3 | HO-1 expression in the kidney 4 h after sham or IR
injury. Upper panel: Western analysis for HO-1 protein expression in
HO-1þ /þ and HO-1/ mice subjected to ischemia–reperfusion injury
(IR) or sham ischemia (Sham). Each lane represents protein extracted
from a single kidney of an individual mouse. Equivalency of protein
loading was verified by Ponceau staining (not shown). Lower panel:
HO-1 mRNA by quantitative real-time reverse transcriptase-PCR in
HO-1þ /þ and HO-1/ mice subjected to ischemia–reperfusion injury
(IR) or sham ischemia (Sham). n¼ 4 in each of the HO-1þ /þ Sham
and HO-1/ Sham groups, and n¼ 6 and n¼ 8 in HO-1þ /þ IR and
HO-1/ IR groups respectively.
Table 1 | Cytokine mRNA expression in the kidney 8 h after
Sham or IR injury
HO-1+/+ Sham HO-1/ Sham HO-1+/+ IR HO-1/ IR
MCP-1 67.1716.0 59.878.9 179.3736.4 397.47159.1
TNF 111.0743.9 78.5723.4 217.2738.9 259.4790.7
ET-1 1.770.2 2.971.3 3.371.0 8.171.7*
IL-10 34.4716.2 33.3716.0 49.8715.8 79.4728.7
ET-1, endothelin-1; HO-1, heme oxygenase-1; IL, interleukin; IR, ischemia–reperfu-
sion; MCP-1, monocyte chemotactic protein-1; RT-PCR, reverse transcriptase-
polymerase chain reaction; Sham, sham ischemia; TNF, tumor necrosis factor.
Cytokine mRNA expression in the kidney 8 h after Sham or IR injury in HO-1+/+ and
HO-1/ mice, and assessed by quantitative real-time RT-PCR. Values are the result
of relative quantification performed against a standard curve constructed for each
mRNA target, normalized for expression of 18S rRNA, and expressed in arbitrary
units. n=4 and n=5 in the HO-1+/+ Sham and HO-1/ Sham groups respectively, and
n=8 and n=7 in the HO-1+/+ IR and HO-1/ IR groups respectively.
*Po0.05 versus HO-1+/+ IR.
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Figure 4 | IL-6 mRNA determination by quantitative real-time
reverse transcriptase-PCR in the kidney in HO-1þ /þ and HO-1/
mice subjected to ischemia–reperfusion injury (IR) or sham
ischemia (Sham). n¼ 4 and n¼ 5 in the HO-1þ /þ Sham and HO-1/
Sham groups respectively, and n¼ 8 and n¼ 7 in the HO-1þ /þ IR
and HO-1/ IR groups respectively. *Po0.05 versus HO-1þ /þ mice
subjected to the same condition.
HO-1+/+ HO-1–/– HO-1+/+ HO-1–/–
IRSham
pSTAT3
STAT3
-Actin
Figure 5 | Western analysis for pSTAT3 and STAT3 expression in
the kidney in HO-1þ /þ and HO-1/ mice subjected to
ischemia–reperfusion injury (IR) or sham ischemia (Sham). Each
lane represents protein extracted from a single kidney of an
individual mouse, and equivalency of protein loading was verified by
immunoblotting for b-actin.
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Expression of IL-6 and pSTAT3 in the lung and heart 8 h after
renal ischemia–reperfusion
Since IL-6 was markedly increased in the kidney and the
systemic circulation, and IL-6 predicts increased mortality in
acutely ill patients,24 expression of IL-6 was assessed in vital
organs such as the heart and lung. In both of these organs,
IL-6 was significantly increased in HO-1/ mice as
compared to HO-1þ /þ mice subjected to ischemia–reperfu-
sion with no differences observed in the sham-operated
animals (Figure 9).
pSTAT3 was also upregulated in distant vital organs. As
demonstrated in Figure 10, HO-1/ mice subjected to
ischemia–reperfusion exhibited significant upregulation in
pSTAT3 in the lung as compared to similarly treated HO-1þ /þ
mice, whereas such upregulation was not observed in HO-1/
or HO-1þ /þ mice subjected to sham ischemia. Such
differential upregulation of pSTAT3 in the lung in HO-1/
mice after ischemia was also seen in the heart (data not
shown).
Mild vascular congestion was observed in the lung and
heart after ischemia–reperfusion injury as compared with
sham ischemia, but these histologic changes were comparable
in HO-1þ /þ and HO-1/ mice at the time point studied,
namely, 8 h (data not shown).
Table 2 | Concentration of cytokines in serum 8 h after Sham
or IR injury
HO-1+/+ Sham HO-1/ Sham HO-1+/+ IR HO-1/ IR
IL-1a 348765 377748 424753 490739
IL-1b 206722 157743 18178 19379
IL-2 2375 3177 1272 51741
IL-3 1171 2175 1472 1072
IL-4 871 1174 871 1073
IL-9 723759 694741 561731 414782
IL-10 250742 4257125 209713 3837122
IL-12 (p70) 800737 15677371 812774 8507438
IL-13 297729 294747 227720 209733
IL-17 368732 468748 318730 176770
Eotaxin 23207174 22657227 19347130 18157176
G-CSF 27417651 25957447 31667400 41827628
GM-CSF 16176 165712 14476 134714
IFN-g 195722 274742 15179 110719
KC 349759 339744 317740 407759
MCP-1 575727 610729 571725 6347117
MIP-1b 6575 104737 86718 5273
RANTES 288739 419768 363736 223737
TNF 1247791 16707252 1128785 10817171
G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte–macrophage
colony-stimulating factor; HO-1, heme oxygenase-1; IFN-g, interferon-g; IL, inter-
leukin; IR, ischemia–reperfusion; KC, keratinocyte-derived chemokine; MIP-1b,
macrophage inflammatory protein; MCP-1, monocyte chemotactic protein-1;
RANTES, regulated on activation normal T-cell expressed and secreted; Sham, sham
ischemia; TNF, tumor necrosis factor.
Concentrations of cytokines in serum (pg/ml) were determined by a protein array
assay 8 h after Sham or IR injury in HO-1+/+ and HO-1/ mice. n=4 and n=5 in the
HO-1+/+ and HO-1/ Sham groups respectively, and n=8 and n=7 in the HO-1+/+ IR
and HO-1/ IR groups respectively.
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Figure 6 | Serum levels of IL-6 in HO-1þ /þ and HO-1/ mice
subjected to ischemia– reperfusion injury (IR) or sham ischemia
(Sham). n¼ 4 and n¼ 5 in the HO-1þ /þ Sham and HO-1/ Sham
groups respectively, and n¼ 8 and n¼ 7 in the HO-1þ /þ IR and
HO-1/ IR groups respectively. *Po0.05 versus HO-1þ /þ mice
subjected to the same condition.
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Figure 7 | Serum levels of IL-12 (p40) in HO-1þ /þ and HO-1/
mice subjected to ischemia– reperfusion injury (IR) or sham
ischemia (Sham). n¼ 4 and n¼ 5 in the HO-1þ /þ Sham and HO-1/
Sham groups respectively, and n¼ 8 and n¼ 7 in the HO-1þ /þ IR
and HO-1/ IR groups respectively. *Po0.05 versus HO-1þ /þ mice
subjected to the same condition.
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Figure 8 | Serum levels of IL-5 and macrophage inflammatory
protein (MIP)-1a in HO-1þ /þ and HO-1/ mice subjected to
ischemia–reperfusion injury (IR) or sham ischemia (Sham). n¼ 4
and n¼ 5 in the HO-1þ /þ Sham and HO-1/ Sham groups
respectively, and n¼ 8 and n¼ 7 in the HO-1þ /þ IR and HO-1/ IR
groups respectively. *Po0.05 versus HO-1þ /þ mice subjected to the
same condition.
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Effect of an IL-6 antibody on the sensitivity of HO-1/ mice
to renal ischemia
Utilizing an IL-6 antibody previously shown to protect
against ischemic kidney injury in wild-type mice,25 we
examined whether IL-6 contributes to the sensitivity of
HO-1/ mice to such ischemia. HO-1/ mice, subjected
to ischemia, were treated either with an IL-6 antibody or an
isotype immunoglobin G (IgG) control antibody (n¼ 13 and
n¼ 14 respectively). The administration of an IL-6 antibody
led to a BUN that was approximately 50% lower at day 1 after
ischemia as compared to that observed in isotype IgG-treated,
ischemic HO-1/ mice (48710 versus 89717 mg/dl,
Po0.05, n¼ 13 and n¼ 11 respectively). Moreover, by day
2 after ischemia, no mortality occurred in the IL-6 antibody-
treated HO-1/ mice subjected to ischemia, whereas in the
isotype IgG-treated HO-1/ mice subjected to ischemia, four
deaths occurred and one moribund animal (agonal BUN:
191 mg/dl) was killed; the administration of an IL-6 antibody
thus significantly decreased mortality from 36 to 0% at day 2
following ischemia in HO-1/ mice.
DISCUSSION
As evidenced by increased BUN and serum creatinine 24 h
after ischemia, our earlier studies demonstrate that HO-1/
mice exhibit increased sensitivity to renal ischemia. Such
sensitivity occurs as early as 4 h after ischemia, as shown in
our current studies and as reflected by GFR. This impairment
in GFR in HO-1/ mice was accompanied by a lower
filtration fraction but was not attended by changes in RBF,
renal vascular resistance, or cardiac output. This filtration
defect may reflect an impairment in such determinants of
GFR as the glomerular ultrafiltration coefficient or the
transcapillary hydraulic pressure gradient, both of which can
be altered by vasoactive species. It is possible that ischemia
may differentially affect the production of vasoactive
mediators in HO-1/ mice as compared to HO-1þ /þ
mice, and in this regard, endothelin-1 was induced to a
greater extent in the postischemic kidney in HO-1/ mice.
Of the cytokines assessed after ischemia, marked induction
of IL-6 occurred in the kidney in HO-1/ mice. IL-6 is a
critical contributor to postischemic kidney injury25,26 as
shown by the following lines of evidence: IL-6/ mice are
resistant to acute ischemic renal injury;25,26 increased
production of IL-6 in the ischemic kidney originates largely
from macrophages, and the reconstitution of IL-6/ mice
with bone marrow from wild-type mice reduces the resistance
of IL-6/ mice to ischemic injury;26 and prior treatment
with an IL-6 antibody reduces renal ischemic injury in wild-
type mice.25 IL-6 may also be relevant to human acute kidney
injury, since urinary excretion of IL-6 is a predictor for such
injury in kidney transplant recipients.27 That IL-6 contributes
to the renal dysfunction in HO-1/ mice following ischemia,
as observed in the current study, is indicated by preservation
of renal function in HO-1/ mice subjected to ischemia,
when these mice are pretreated with an IL-6 antibody.
IL-6 exerts its cellular effects, in part, via the pSTAT3
member of the JAK/STAT system,23,28 and in the present
studies, expression of pSTAT3 mirrored the profile observed
for IL-6: marked upregulation of pSTAT3 occurred in the
kidney of HO-1/ mice after ischemia but not in the other
three groups. These findings are germane to recent and novel
observations demonstrating the proapoptotic actions of
pSTAT3 in kidney cells.29 Based on these latter findings29
and our current observations we suggest that IL-6/pSTAT3
contribute to cytoreductive pathways and renal injury in
HO-1/ mice following renal ischemia.
Our earlier studies demonstrate that the sensitivity of
HO-1/ mice to renal ischemia was accompanied by
increased mortality.22 To explore the basis for such sensitivity,
we assessed the expression of cytokines in the systemic
circulation and in vital organs such as the heart and lung. Of
the cytokines measured in serum, IL-6 was markedly and
uniquely elevated in HO-1/ mice as compared with HO-
1þ /þ mice following ischemia; the only other cytokine that
was increased in HO-1/ mice after ischemia was IL-12
(p40), but this latter cytokine was also increased in HO-1/
mice as compared with HO-1þ /þ mice following sham
ischemia. IL-6 can induce an acute phase response and reach
target organs distant from its site of production.23,28 IL-6 is
one of a few cytokines that predict mortality in acutely ill
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Figure 9 | IL-6 mRNA determination by quantitative real-time
reverse transcriptase-PCR in the heart and lung in HO-1þ /þ and
HO-1/ mice subjected to ischemia–reperfusion injury (IR) or
sham ischemia (Sham). For studies in either organ, n¼ 4 and n¼ 5
in the HO-1þ /þ Sham and HO-1/ Sham groups respectively, and
n¼ 8 and n¼ 7 in the HO-1þ /þ IR and HO-1/ IR groups
respectively. *Po0.05 versus HO-1þ /þ mice subjected to the same
condition.
HO-1+/+ HO-1–/– HO-1+/+ HO-1–/–
Sham IR
pSTAT3
STAT3
-Actin
Figure 10 | Western analysis for pSTAT3 and STAT3 expression in
the lung in HO-1þ /þ and HO-1/ mice subjected to
ischemia–reperfusion injury (IR) or sham ischemia (Sham). Each
lane represents protein extracted from a single lung of an individual
mouse, and equivalency of protein loading was verified by
immunoblotting for b-actin.
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patients with acute renal failure24 and in those patients with
chronic kidney disease either initiated or maintained on chronic
hemodialysis.30,31 Based on these considerations, in general, and
our findings derived from the use of the IL-6 antibody, in
particular, we suggest that the marked and unique elevation in
systemic levels of IL-6 may contribute to increased mortality
observed in HO-1/ mice following renal ischemia. IL-12
(p40), a proinflammatory cytokine, was increased in HO-1/
mice even in the absence of ischemia, and it is possible that such
upregulation of IL-12 (p40) may also be germane to the
observed sensitivity of HO-1/ mice to ischemia.
In distant vital organs such as the heart and lung, IL-6 was
upregulated in HO-1/ mice subjected to renal ischemia,
and was accompanied by upregulation of its downstream
signaling species, pSTAT3. This raises the possibility that such
upregulation of IL-6/pSTAT3 in these organs may contribute
to organ dysfunction. Prior, novel studies demonstrate the
adverse extrarenal effects of localized ischemic injury to the
kidney.3,6,9–12 For example, renal ischemic injury increases
pulmonary vascular permeability9,11 and cytokine expression
in the heart, causes apoptosis of myocytes, and impairs
cardiac function.10 The mechanisms incriminated in the relay
of information from the ischemic kidney to these vital
extrarenal organs involve cytokines including IL-6.3,6,9–12
The duration of renal ischemia employed in this study
(15 min) was relatively mild, and in HO-1þ /þ mice, failed to
impair renal hemodynamics, to elevate serum IL-6, or to
induce IL-6/pSTAT3 in the kidney and other organs.
However, as recently shown, relatively mild renal ischemia
can amplify the inflammatory effects of lipopolysaccharide.32
Furthermore, when cytoprotective responses are abrogated—
as occurs in HO-1/ mice—these regional and distant
effects of relatively mild, localized, renal ischemia can be
accentuated. Similarly, in the setting of a disease that
promotes a proinflammatory and procoagulant state, such
as sickle cell disease, relatively mild renal ischemia can inflict
severe injury to the kidney and distant organs.33
The marked upregulation of IL-6 mRNA in the ischemic
kidney and in the nonischemic heart and lung in HO-1/
mice suggests that the inability to express HO-1 in these
stressed tissues promotes the upregulation of IL-6. Renal
ischemia can induce expression of HO-1 in the heart,34 and it
is thus possible that the absence of expression of HO-1 in
distant organs (such as the heart and lung) of HO-1/ mice
subjected to renal ischemia may underlie the upregulation of
IL-6 observed in these organs. We also suggest that, as IL-6
can induce HO-1,35,36 a negative feedback loop may exist
between IL-6 and HO-1 such that induction of IL-6
upregulates HO-1 which, in turn, exerts a countervailing,
suppressive effect on IL-6 expression.
Kidney and other diseases occur in humans with genetic
deficiency of HO-1,37,38 and polymorphisms in the HO-1
gene associated with lesser HO activity may predispose to
assorted diseases.39 The exaggerated inflammatory response
observed in this and earlier studies of HO-1/ mice
subjected to ischemic and nephrotoxic insults40–43 raises the
possibility that inflammatory processes may contribute to
morbidity and mortality in acutely ill patients in whom
HO-1 is deficient or inadequately expressed.
In summary, we demonstrate that within hours of
relatively mild renal ischemia, an HO-1-deficient state
exhibits increased renal dysfunction accompanied by in-
creased IL-6/pSTAT3 in the kidney and distant vital organs,
and markedly increased systemic levels of IL-6. Based on
studies utilizing an IL-6 antibody, we suggest that the
regional, systemic, and distant upregulation of IL-6 con-
tributes to the adverse renal and extrarenal responses to acute
renal ischemia observed in an HO-1-deficient state.
MATERIALS AND METHODS
Murine HO-1/ model
Homozygous HO-1 null mutant mice, employed in this and earlier
studies by our laboratory22,40,42, were generated by targeted
disruption of the HO-1 gene as described by Poss and Tonegawa.44
Colonies of mice were maintained by breeding HO-1/ males with
HO-1þ / females. Offspring were genotyped at the time of weaning
by using polymerase chain reaction (PCR) to amplify the wild-type
and mutant alleles of genomic DNA from tail samples. HO-1þ /þ
mice were used as controls. For all experiments, HO-1þ /þ and
HO-1/ mice were age-matched and sex-matched, and mice from
9 to 12 weeks were utilized in studies involving renal and
cardiac hemodynamics, and in all studies of cytokine expression
in tissues and serum. All experiments were performed in accordance
with the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health and approved by the Institutional
Animal Care and Use Committee of the Mayo Clinic.
Murine model of acute renal ischemia
This model was performed as described in detail by our earlier
studies.22,33 A midline abdominal incision was made and the renal
pedicles were dissected. Fifteen minutes of bilateral renal ischemia
were induced with non-traumatic clamps (RS5426, Micro Aneurysm
clip, straight, 10 mm, 125 g pressure; Roboz Surgical Instruments,
Rockville, MD, USA). Sham procedures included the abdominal
incision but excluded renal pedicle dissection and clamping.
Renal hemodynamic studies in mice
These studies were performed as described in detail in our earlier
studies.45 Mice were anesthetized with sodium pentobarbital (60 mg/
kg body weight, intraperitoneally) and placed on a temperature-
regulated table to maintain body temperature at 371C. Evaluation of
MAP, RBF, and GFR were commenced after exactly 4 h of reperfusion.
During these studies, a solution of 0.9% saline containing 2.25% of
bovine serum albumin and 0.75% of FITC-inulin (Sigma-Aldrich,
St Louis, MO, USA) was infused, and GFR was determined by the
clearance of inulin.46 RBF was determined by an electromagnetic flow
probe (Transonic Systems Inc., Ithaca, NY, USA) and a small animal
blood flow meter (T206, Transonic Systems Inc.).47 Renal vascular
resistances were calculated as the ratio of MAP/RBF. Renal plasma
flow (RPF) was determined by RBF(100hematocrit)/100. Filtration
fraction was calculated as GFR/RPF.
Assessment of cardiac function after renal ischemia
This methodology is described in detail by our earlier studies.48,49
Echocardiography (c256 and 15L8, Acuson, Mountain View, CA,
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USA) was performed in lightly sedated mice 4 h after renal ischemia
or sham ischemia in HO-1þ /þ and HO-1/ mice. Images were
digitally acquired and stored for off-line blinded analysis. Echo-
cardiographic measurements of left ventricular dimensions were
recorded at end-diastole (EDD) and end-systole (ESD) from three
consecutive cardiac cycles using the leading edge method. Left
ventricular fractional shortening (%FS) was calculated as:
%FS¼ [(EDDESD)/EDD]100. Ejection time (Et) was determined
from the actual pulsed-wave Doppler tracings on the parasternal
long-axis view of trans-aortic flow by measuring the interval from
the beginning of the acceleration to the end of the deceleration. The
myocardial velocity of left ventricular circumferential shortening
(Vcf expressed in circumferences per second) was calculated as:
Vcf¼ [(EDDESD)/EDD]/Et. Stroke volume was determined by the
sum of aortic root cross-sectional area and the velocity time integral,
taken from peak left ventricular outflow tract Doppler tracings. The
product of stroke volume and heart rate, expressed as ml/min, was
used to calculate cardiac output and corrected for body weight.
Western analysis
Western analysis was carried out on proteins extracted from mouse
tissues as described previously.22 Briefly, lysate proteins (20–100mg)
were separated on 10% Tris-HCl gels and transferred to polyvinylidene
fluoride membranes. Blots were incubated with primary antibodies to
pSTAT3 and STAT3 (catalog numbers 9138 and 4904, respectively; Cell
Signaling Technology, Danvers, MA, USA), HO-1 (catalog number
SPA-895; StressGen, Ann Arbor, MI, USA), and b-actin (catalog
number 612657; BD Transduction Laboratories, San Diego, CA, USA)
overnight at 41C. This was followed by incubation with goat anti-
mouse or anti-rabbit IgG secondary antibodies and visualization using
a chemiluminescence method (Amersham Pharmacia, Piscataway, NJ,
USA). Equal protein loading was confirmed by Ponceau staining for
HO-1 or immunoblotting against b-actin for pSTAT3.
mRNA expression by quantitative real-time reverse tran-
scriptase-PCR
For analysis of gene expression, total RNA was extracted from mouse
tissues using the TRIzol method (Invitrogen, Carlsbad, CA, USA) and
further purified with an RNeasy Mini kit (Qiagen, Valencia, CA,
USA), according to each manufacturer’s protocol. One hundred
nanograms of purified total RNA were subsequently used in 20ml
reverse transcription reactions (Transcriptor First Strand cDNA
Synthesis kit, Roche Applied Science, Indianapolis, IN, USA)
employing random hexamers. The resulting cDNA was used in
quantitative real-time PCR analysis as in our earlier study.22 Reactions
were performed on an ABI Prism 7900HT (Applied Biosystems, Foster
City, CA, USA) using TaqMan Mastermix reagents (part number
4309169, Applied Biosystems) with primer and probe concentrations
of 300 nmol/l and 200 nmol/l, respectively. Parameters for quantitative
PCR were as follows: 10 min at 951C, followed by 40 cycles of
amplification for 15 s at 951C, and 1 min at 601C. Probe and primer
sets employed for quantification were designed with Primer Express
software (Applied Biosystems) and are detailed in Table 3. Addition-
ally, a probe and primer set for the analysis of ET-1 gene expression
was obtained from Applied Biosystems (TaqMan Gene Expression
Assay, stock number Mm00438656) and was utilized in quantitative
real-time PCR reactions with cycling parameters outlined above.
Serum protein array assay
This array determined the serum levels of the following cytokines:
interferon-g, TNF, IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9,
IL-10, IL-12 (p40), IL-12 (p70), IL-17, granulocyte colony-
stimulating factor, granulocyte–macrophage colony-stimulating
factor, keratinocyte-derived chemokine, regulated on activation
normal T-cell expressed and secreted, IL-13, Eotaxin, monocyte
chemotactic protein-1, macrophage inflammatory protein-1a, and
macrophage inflammatory protein-1b. Serum samples were col-
lected using BD Microtainer serum separators (BD, Franklin Lakes,
NJ, USA) and concentrations of cytokines were determined
employing a multiplex bead suspension array (23-Plex Mouse
Cytokine Panel, catalog number 171-F11241, Bio-Rad Laboratories,
Hercules, CA, USA) performed on a Bio-Plex Suspension Array
System (Bio-Rad, catalog number 171-000001); this was performed
as described in the manufacturer’s protocol contained in the
Bio-Rad publication number 4110004.
Effect of an IL-6 antibody on the sensitivity of HO-1/ mice
to renal ischemia
To determine the role of IL-6 in the sensitivity of HO-1/ mice to
ischemia, a neutralizing monoclonal rat anti-mouse IL-6 antibody
(catalog number AMC0862, Biosource International, Camarillo, CA,
USA) or an IgG1 isotype control was administered to HO-1/ mice
(10mg/day, intraperitoneally) at 24 h and 1 h before, and 24 h after
renal ischemia (15 min bilateral renal ischemia, as described above);
these studies were performed in 40-week-old male HO-1/ mice.
For these studies, renal function was assessed by the measurement of
BUN levels at 24 h after ischemia using a BUN Analyzer 2 (Beckman
Instruments, Fullerton, CA, USA).
Table 3 | Primers and probes used for quantitative real-time
RT-PCR
Gene Primer/Probe Sequence
HO-1 Forward 50-CTGCTAGCCTGGTGCAAGATACT-30
Reverse 50-GTCTGGGATGAGCTAGTGCTGAT-30
TaqMan 50-(FAM)-AGACACCCCGAGGGAAACCCCA
(TAMRA)-30
IL-6 Forward 50-CCAGAAACCGCTATGAAGTTCCT-30
Reverse 50-CACCAGCATCAGTCCCAAGA-30
TaqMan 50-(FAM)TCTGCAAGAGACTTCCATCCAGTTGCC
(TAMRA)-30
IL-10 Forward 50-AGCAGCCTTGCAGAAAAGAGA-30
Reverse 50-AGTAAGAGCAGGCAGCATAGCA-30
TaqMan 50-(FAM)-CCATCATGCCTGGCTCAGCA
(TAMRA)-30
MCP-1 Forward 50-GGCTCAGCCAGATGCAGTTAA-30
Reverse 50-CCTACTCATTGGGATCATCTTGCT-30
TaqMan 50-(FAM)-CCCCACTCACCTGCTGCTACTCATTCAC
(TAMRA)-30
TNF Forward 50-TCTCTTCAAGGGACAAGGCTG-30
Reverse 50-ATAGCAAATCGGCTGACGGT-30
TaqMan 50-(FAM)-CCCGACTACGTGCTCCTCACCCA
(TAMRA)-30
18S Forward 50-TGTCTCAAAGATTAAGCCATGCAT-30
Reverse 50-AACCATAACTGATTTAATGAGCCATTC-30
TaqMan 50-(FAM) TACGCACGGCCGGTACAGTGAAACT
(TAMRA)-30
HO-1, heme oxygenase-1; IL, interleukin; MCP-1, monocyte chemotactic protein-1;
RT-PCR, reverse transcriptase-polymerase chain reaction; TNF, tumor necrosis factor.
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Statistics
Data are expressed as mean7s.e.m. Data for HO-1/ and HO-1þ /þ
mice for a given condition were compared using Student’s t-test for
parametric data, and the Mann–Whitney test for nonparametric data.
Results were considered significant for Po0.05.
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